 |
Markowitz Receives Hamdan Award for Medical Research Excellence
The Case Comprehensive Cancer Center celebrates
Dr. Sanford (Sandy) Markowitz's selection by an international jury as a 2016 recipient of a prestigious Hamdan Award for Medical Research Excellence. Dr. Markowitz journeyed to Dubai for the December 14th award ceremony and to deliver his award address. Presentation of the $27,000 award was made by H.H. Sheikh Hamdan Bin Rashid Al Maktoum, the Deputy Ruler of Dubai and Minister of Finance of the United Arab Emirates.
2016 marked the ninth presentation of the biennial Hamdan medical research excellence awards, with past Hamdan awardees now including four winners of the Lasker Award and one Nobel Laureate.
|
|
|
Markowitz shakes hands with
H. H. Sheik Hamdan Bin Rashid Al Maktoum, Deputy Ruler of Dubai and Minister of Finance of the United Arab Emirates
|
The topic of the 2016 awards was recognizing advances in gastrointestinal diseases. Markowitz's award, for achievements in colon diseases, recognized his work in discovering two colon cancer suppressor genes, TGF-beta RII and 15-PGDH, that explain how and why patients with Lynch syndrome develop colon cancer, and also recognized his work in developing molecular tests for early detection of GI cancers. Other 2016 awardees included Dr. Harvey Alter, from the National Institutes of Health, recognized for his discovery of hepatitis C, and Dr. David Tuveson, deputy director of the Cold Spring Harbor Cancer Center, recognized for his work on pancreatic cancer. Markowitz is the Markowitz-Ingalls Professor of Cancer Genetics at the Case School of Medicine, co-Leader of the GI Cancer Genetics Program at the Case Comprehensive Cancer Center, and a physician at University Hospitals Seidman Cancer Center.
|
Meiosis is a specialized cell division used for gamete formation by all sexually reproducing organisms, including animals, plants, and humans. During meiosis the proteasome assists in regulating the concentration of particular proteins and degrading misfolded proteins, in a process known as proteolysis. However, the significant impact of proteolytic activity on events leading up to chromosome segregation during meiosis was unknown until now.
 |
|
|
Valentin Boerner
|
"Key events of meiosis involve the pairing and crossing over between homologous chromosomes," says
Valentin Börner, Case Comprehensive Cancer Center, leader of the research team and an associate professor with Cleveland State University's
Center for Gene Regulation in Health and Disease. "Our findings show that the proteasome controls both processes via its proteolytic activity. Errors in this activity could be the reason for chromosomal instabilities which cause miscarriages, birth defects such as Down syndrome and cancer. This is the first case where proteolytic activity has been implicated in large-scale changes in chromosome pairing."
more>
|
DiFeo Co-Director of Athymic Animal & Xenograft Core Facility
|
|
|
Analisa DiFeo
|
Analisa DiFeo, PhD, Case Comprehensive Cancer Center, Assistant Professor, General Medical Sciences - Oncology, Case Western Reserve University, is now co-Director of the
Athymic Animal & Xenograft Core Facility, along with current Director
Dan Lindner, MD, PhD,
Assistant Professor, Cancer Biology, Cleveland Clinic.
We would also like to remind people of the following price changes that went into effect September 2016:
NSG (NOD/SCID/IL2Rgamma)=$50
Athymic NCR nu/nu=$40
Athymic NOD/SCID=$45
|
| 1st Annual Cancer Disparities Symposium: Building Bridges to Address Cancer Disparities
March, 17, 2017 | Cleveland, OH
The Case Comprehensive Cancer Center is excited to announce the
inaugural Cancer Disparities Symposium: Building Bridges to Address Cancer Disparities. Understanding and addressing cancer disparities is complex and multi-faceted, and requires attention across the translational spectrum. This half-day event will showcase cutting-edge research, with a focus on reducing and eliminating disparities in cancer, going from bench-to-bedside-to-community and back. This important symposium will also feature two keynote addresses, including a key leader in our community, and an internationally-recognized cancer disparities researcher. We will promote the exchange of ideas and collaborative opportunities among scientists, clinicians, government, and community representatives.
Please save the date! More information to follow.
|
CWRU's Dr. Ruth Keri on Misunderstandings in Cancer Research, Underrepresentation of Women in Science, and NIH Funding
Cleveland Scene - Jan 4 2017
Today, that's a conversation with Dr. Ruth Keri, Associate Director for Basic Research at Case Comprehensive Cancer, to talk about her career in science, the current state of research in Cleveland, the underrepresentation of women in science, and common misunderstandings about cancer research...
|
WJHG.com - Dec 28, 2016
For men with prostate cancer, androgen deprivation therapy, or ADT, is a common course of treatment.
The testosterone reducing therapy is first-line treatment for prostate cancer that has spread to stop its growth. Now a recent study suggests that long term use of ADT is associated with an increased risk for dementia.
Dr. Eric Klein did not take part in the study, but treats prostate cancer at Cleveland Clinic.
"There's always been this question about whether testosterone is really required for good brain function in older men and so the study went a step further and looked at whether or not men who had been on androgen deprivation therapy for some time have a higher incidence of dementia and that's in fact what it showed, about double the incidence of dementia," explains Dr. Klein.
|
Colon cancer in millennials? Two Cleveland area women warning others about rare diagnosis
14news.com - Dec 27, 2016
A 25-year-old woman received devastating news of a diagnosis that's extremely rare in young people. Deanna Pisano had just returned from her honeymoon when she received the diagnosis...
Colon cancer is extremely rare in young people.
Dr. John Letterio, Case Comprehensive Cancer Center, is a Pediatric Oncologist for University Hospitals. He said the majority of colon cancer cases are found in people over 50. Family history can put you at risk and so can obesity.
"A healthy lifestyle meaning physical activity - exercising as much as possible. Diet is a big thing with respect to colon cancer. We always recommend lowering the amount of red meat you intake - particularly processed meats," said Letterio.
|
| New treatment could prevent hair loss during chemotherapy
WJHG.com - Dec 26, 2016
Hair loss is one of the top concerns for women undergoing chemotherapy for breast cancer. When a woman loses her hair during chemo, it can be constant reminder of the cancer and often causes anxiety and depression.
Now, research presented shows a special "cooling" cap may help some women undergoing treatment for early stage breast cancer keep their hair.
Cleveland Clinic and Case Comprehensive Cancer Center's
Dr. Jame Abraham co-authored the study and says the findings are significant.
"In patients who used this cap, there is about a fifty percent reduction in hair loss," says Dr. Abraham.
|
cleveland.com - Dec 23, 2016
Tiny machines smaller than a human hair may hold the key to shrinking cancer cells or prolonging remission. A new collaboration between the
Cleveland Clinic and the
Hebrew University of Jerusalem aims to find out if that's possible.
The collaboration, named the
Center for Transformative Nanomedicine
, combines research teams from the Clinic and Hebrew University in a quest to determine if nanomedicine can effectively deliver treatments to brain and breast cancers, said Dr. Geoffrey Vince, chair of biomedical engineering at Cleveland Clinic. He is leading the center's efforts in Cleveland. Cleveland Clinic and Case Comprehensive Cancer Center doctors involved in both projects are
Dr. Stephen Grobmyer, Dr. Charis Eng and Dr. Jeremy Rich.
|
Yahoo News - Dec 22, 2016
According to disturbing new research, cases of
melanoma, the most deadly form of
skin cancer, are on the rise in the U.S. More Americans are also dying of the disease than they did seven years ago.
The findings come courtesy of a
JAMA Dermatology
study that analyzed cases of melanoma in 2009 and 2016...Brian Gastman, MD, Case Comprehensive Cancer Center plastic surgeon, medical and surgical director of melanoma at Cleveland Clinic, tells Yahoo Beauty that doctors are getting better at picking up melanomas, which may explain the increase in numbers. However, Goldenberg says, incidents of the cancer are increasing, especially in young patients. "This is directly related to the amount of sun exposure patients are still getting," he says.
|
The disgrace of cancer clinical trials
The Hill - Dec 21, 2016
Editorial by Mikkael Sekeres, MD, MS, director, leukemia program and the vice-chair for clinical research at Cleveland Clinic Taussig Cancer Institute and Deputy Associate Director for Clinical Research and Director, Clinical Trials, Case Comprehensive Cancer Center...A woman battling leukemia sat across from me the other day, eager to hear the news: Would she qualify to be part of a clinical research trial? Or not? Her quandary is far too common. Thousands of adult cancer patients with limited available treatment options are considered for clinical trials, but fewer than five percent are actually selected. |
Pancreatic Cancer Action Network
The Pancreatic Cancer Action Network is now accepting applications for 2017 funding opportunities:
Deadline: February 15, 2017, Noon EST
This Request for Applications is to solicit Precision Medicine Targeted Grant applications to provide funding for projects that can be incorporated directly into the Pancreatic Cancer Action Network's Precision Promise initiative at the end of the funding period. Applications for any amount of money up to $1 million total (direct plus a maximum of 20 percent indirect costs) for a time period up to two years are solicited. Applications from academic institutions or for-profit biotechnology or pharmaceutical firms are accepted.
Deadline: February 22, 2017, Noon EST
This Request for Applications is to support ancillary research studies that identify promising blood biomarkers or imaging approaches that will eventually facilitate the use of specimens and/or participants in a cohort of new-onset diabetics and validate components of a protocol for the early detection of pancreatic ductal adenocarcinoma. Applicants may propose up to four Units, (or projects) with a specific goal and clearly defined, quantifiable outcome measures. Each Unit must indicate a separate budget, not to exceed $250,000, for a period of up to two years. The total amount requested may not exceed $1 million total for a total time period of four years.
|
NIH BULLETIN- Notices and Funding Opportunities
|
|
|
|
FOLLOW US
|
|
Mon, Jan 9
GMI Seminar
Stetson Thacker
Eng Lab, Genomic Medicine Institute, Cleveland Clinic
"An Exploration of the Neural Phosphoproteome of a High Functioning Model of Autism with a Constitutional Pten Mutation"
12:30p NE1-205 Cleveland Clinic |
|
Tues, Jan 10
Radiation Oncology Grand Rounds
Ashley Sekhon, MD
Radiation Oncology, Ohio State
"Improving the Therapeutic Ratio in Breast Radiotherapy"
8:10a Lerner B-151
THOR Seminar
Jacob Scott, MD
Associate Staff, THOR & Radiation Oncology, Cleveland Clinic
1p R3-027
Cancer Center Research in Progress Seminar
Anil Belur Nagaraj, PhD
Research Associate, General Medical Sciences - Oncology, DiFeo Lab, CWRU
"Exploring miRNA functioning in 'real-time': A novel miRNA sensor platform to delineate regulation of tumor-initiation properties by miRNAs in cancers"
3p WRB 3-136 |
|
Wed, Jan 11
HemOnc Research Conf
8a Lerner B-151
PRCHN Seminar Series
Monica Webb Hooper, PhD
Professor, Div. of General Medical Sciences-Oncology, CWRU
Director, Office of Cancer Disparities Research, Case Comprehensive Cancer Center
"Health Psychology Research to Address Tobacco Use and Related Disparities"
12p PRCHN Conf Rm |
|
Fri, Jan 13
HemOnc Fellows
8a Breen Conf Rm
Taussig Cancer Institute Grand Rounds
David Rimm, MD
Yale University
"Companion Diagnostic Tests for PD-L1- based Immune Therapy"
8a R3/002-003
Cancer Center Seminar Series
Peter Nelson, MD
Professor, Medical Oncology, University of Washington Medicine
Genitourinary Oncology Clinical Research Director, Seattle Cancer Care Alliance
"Molecular Landscapes of Advanced Prostate Cancers: Opportunities for Developing Therapeutics and Guiding Treatment"
12p BRB 105
|
ADDITIONAL UPCOMING SYMPOSIUMS & EVENTS
ASH Review
Jan 25, 2017
InterContinental Hotel
1st Annual Cancer Disparities Symposium: Building Bridges to Address Cancer Disparities
Mar 17, 2017
Wolstein Research Bldg
NCCN 22nd Annual Conference: Improving the Quality, Effectiveness, and Efficiency of Cancer Care™
Mar 23-25, 2017
GvHD National Symposium
Oct 13, 2017
Grand Event Center, Columbus, OH
|
PREVIOUSLY ANNOUNCED OPPORTUNITIES
Deadline: Jan 13, 2017
LOI Deadline: Feb 1, 2017
Invited Full Proposal Deadline: Mar 15, 2017
LOI Deadline:
Feb 1, 2017
Deadline: Open
Deadline: Open
Deadline: Open
|
|
|
|
